Plexxikon Inc.

Plexxikon Inc. is a biotechnology company founded in 2000 and headquartered in the United States. As a member of the Daiichi Sankyo Group, Plexxikon specializes in the discovery and development of innovative, small molecule pharmaceuticals through its proprietary discovery platform. The company has achieved significant success with its portfolio of clinical and preclinical stage programs in various therapeutic areas and disease indications. One of its notable accomplishments is the discovery of ZELBORAF® (vemurafenib) tablets, previously known as PLX4032, in 2005, with the first clinical trial initiated in 2006. This mutation-specific medicine, co-developed with partner Roche, has garnered approval in over 40 countries worldwide. The company's demonstrated capability in discovery and early development, combined with a diverse pipeline and an experienced management and scientific team, positions Plexxikon uniquely to create significant value for the company and its collaborators. The most recent investment in Plexxikon was a $7.49M Series B funding round on 01 March 2005.